Comparative Pharmacology
Head-to-head clinical analysis: FLOLAN versus VERTAVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOLAN versus VERTAVIS.
FLOLAN vs VERTAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epoprostenol is a prostaglandin I2 (prostacyclin) analogue that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and has antiproliferative effects on vascular smooth muscle.
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Initial: 4 ng/kg/min via continuous IV infusion, then titrated in increments of 1-2 ng/kg/min at intervals of at least 15 minutes based on clinical response. Typical maintenance dose: 20-40 ng/kg/min; range: 10-80 ng/kg/min.
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
None Documented
None Documented
3–5 minutes (terminal elimination half-life; rapid inactivation necessitates continuous IV infusion).
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Renal: 70% (as inactive metabolites); biliary/fecal: negligible.
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Category C
Category C
Prostacyclin Vasodilator
Prostacyclin Vasodilator